11 / 22
The longest OS with pembrolizumab monotherapy*
was seen in those with the highest PD-L1 expression
Pembro mono* (n=133)
EXTREME (n=122)
Median OS, months (95% CI)
14.9 (11.6–21.5)
10.7 (8.8–12.8)
Pembro mono* (n=257)
EXTREME (n=255)
Median OS, months (95% CI)
12.3 (10.8–14.9)
10.3 (9.0–11.5)
CPS ≥20
0
0
10
20
30
40
50
60
70
80
90
100
Percent survival (%)
5 10 15 20 25 30 35 40
Months
133 106 85 65 47 24 11 2 0
122 100 64 42 22 12 5 0 0
No. at risk
12-month rate
56.9%
44.9%
24-month rate
38.3%
22.1%
p=0.0007
Total events
62%
78%
12-month rate
51.0%
43.6%
24-month rate
30.2%
18.6%
Percent survival (%)
0
0
5 10 15 20 25 30 35 40
Months
257 196 152 110 74 34 17 2 0
10
20
30
40
50
60
70
80
90
No. at risk
100
255 207 131 89 47 21 9 1 0
CPS ≥1
p=0.0086
Total events
69%
81%
HR: 0.61 (0.45-0.83)
HR: 0.78 (0.64-0.96)